Integration of Lutetium Lu 177 Vipivotide Tetraxetan Highlights Potential of Radioligands in Prostate Cancer
The FDA approval of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) brought radioligand therapy to the prostate cancer treatment paradigm, and further research with this agent and others in this class could establish a broader role for this type of …